DeepMed Research

Paricalcitol

Generic Name: Paricalcitol

Brand Names: Zemplar

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₄O_₃

CAS Number: 131918-61-1

Unique Ingredient Identifier: 6702D36OG5

Background: Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Indication: For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Associated Conditions: Secondary Hyperparathyroidism (SHPT)

Clinical Trials

Effect of Paricalcitol Over Vessel Wall

Phase 4

Terminated

Conditions: Nephropathy

Interventions: Drug: Paricalcitol

First Posted Date: 2015-02-26

Last Posted Date: 2015-02-26

Lead Sponsor: Effice Servicios Para la Investigacion S.L.

Target Recruit Count: 50

Registration Number: NCT02372695

Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Paricalcitol Capsules, 4 mcg

First Posted Date: 2014-12-23

Last Posted Date: 2014-12-23

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 69

Registration Number: NCT02322632

Locations: 🇮🇳
Lambda Therapeutic Research Ltd, Ahmedabad, Gujarat, India

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

Phase 3

Completed

Conditions: Chronic Kidney Disease
Hyperparathyroidism, Secondary
Vitamin D Deficiency

Interventions: Drug: CTAP101 Capsules
Drug: Calcitriol
Drug: Doxercalciferol
Drug: Paricalcitol

First Posted Date: 2014-11-04

Last Posted Date: 2016-09-29

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 298

Registration Number: NCT02282813

Paricalcitol in Fabry Disease

Not Applicable

Completed

Conditions: Fabry Disease
Proteinuria

Interventions: Drug: Paricalcitol

First Posted Date: 2014-03-18

Last Posted Date: 2014-03-18

Lead Sponsor: Federico II University

Target Recruit Count: 14

Registration Number: NCT02090608

Locations: 🇮🇹
federico II university, department of nephrology, Naples, Italy

A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas

Interventions: Drug: Paricalcitol
Drug: Gemcitabine
Drug: Abraxane

First Posted Date: 2014-01-09

Last Posted Date: 2024-02-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 15

Registration Number: NCT02030860

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism Due to Renal Causes

Interventions: Drug: Calcifediol
Drug: Paricalcitol

First Posted Date: 2013-09-11

Last Posted Date: 2018-11-19

Lead Sponsor: Fundación Senefro

Target Recruit Count: 148

Registration Number: NCT01939977

Locations: 🇪🇸
Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain
🇪🇸
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
🇪🇸
Hospital Puerta Del Mar, Cádiz, Spain

and more 13 locations

Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Paricalcitol, atorvastatin
Drug: Paricalcitol
Drug: Atorvastatin

First Posted Date: 2013-03-29

Last Posted Date: 2018-08-24

Lead Sponsor: Ricardo Mouzo Mirco

Target Recruit Count: 31

Registration Number: NCT01820767

Locations: 🇪🇸
Hospital El Bierzo. Servicio de Nefrología., Ponferrada, (León)., Spain
🇪🇸
Hospital de León, León, Spain

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease

Not Applicable

Conditions: Type 2 Diabetes
Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: Zemplar

First Posted Date: 2013-02-15

Last Posted Date: 2013-02-15

Lead Sponsor: Scott and White Hospital & Clinic

Target Recruit Count: 60

Registration Number: NCT01792206

Locations: 🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸
Omaha VA Medical Center, Omaha, Nebraska, United States
🇺🇸
Joslin Diabetes Clinic, Inc., Boston, Massachusetts, United States

and more 1 locations

Paricalcitol Effect on Anemia in CKD

Phase 4

Completed

Conditions: Anemia
Chronic Kidney Disease

Interventions: Drug: Calcitriol
Drug: Paricalcitol

First Posted Date: 2013-01-15

Last Posted Date: 2014-07-30

Lead Sponsor: Federico II University

Target Recruit Count: 60

Registration Number: NCT01768351

Locations: 🇮🇹
Federico II University, Naples, Italy

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

Phase 4

Terminated

Conditions: Kidney Failure
Secondary Hyperparathyroidism
Hyperphosphatemia
Hypercalcemia

Interventions: Drug: Calcitriol
Drug: Paricalcitol

First Posted Date: 2012-11-12

Last Posted Date: 2023-11-07

Lead Sponsor: Winthrop University Hospital

Target Recruit Count: 16

Registration Number: NCT01725113

Locations: 🇺🇸
Winthrop University Hospital, Mineola, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy